Physician profile
Eman Rashed
NPI 1851788657
$7,481.72
in general payments reported to CMS, 2019-2025
22 companies · $4,483 in 2025
The $4,483 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $190 · 2024: $2,808 · 2025: $4,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,350 · Travel and Lodging: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,349.60 |
| Travel and Lodging | $2,132.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,381.54 | 2024-2025 | Corevalve Evolut R |
| Cvrx, INC. | $2,031.97 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $843.33 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $461.08 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Paragonix Technologies, INC. | $240.81 | 2024 | Sherpapak, Pancreaspak, Liverguard |
| Boston Scientific Corporation | $240.70 | 2025 | General - Therapies, Enroute Transcarotid Neuroprotection System |
| Shockwave Medical, INC | $185.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $184.81 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.61 | 2024-2025 | Jardiance |
| Heartflow, INC. | $127.28 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.99 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $95.81 | 2023-2025 | Amvuttra, Onpattro |
| Irhythm Technologies, INC. | $95.60 | 2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $95.39 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $48.74 | 2023-2025 | Wainua |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.17 | 2024-2025 | Verquvo |
| One Lambda, INC. | $28.19 | 2024 | |
| Endotronix, INC. | $21.30 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Scpharmaceuticals INC. | $16.75 | 2025 | |
| Invivyd INC | $15.12 | 2025 | Pemgarda |
| Bayer Healthcare Pharmaceuticals INC. | $14.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Rashed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.